Adaptive Biotechnologies (ADPT) Current Assets (2018 - 2026)

Adaptive Biotechnologies has disclosed Current Assets across 9 years of filings, most recently posting $291.8 million for Q1 2026.

• Current Assets for Q1 2026 came in at $291.8 million, up 13.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $291.8 million (up 13.77% YoY), and the FY2025 annual result was $300.2 million, up 5.79% from the prior year.
• Current Assets came in at $291.8 million for Q1 2026 at Adaptive Biotechnologies, down from $300.2 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $564.4 million in Q3 2022 to a low of $256.5 million in Q1 2025.
• The 5-year median for Current Assets is $374.0 million (2024), against an average of $383.4 million.
• Peak annual rise in Current Assets reached 39.58% in 2022, while the deepest fall reached 45.21% in 2022.
• Adaptive Biotechnologies' Current Assets stood at $562.1 million in 2022, then declined by 27.03% to $410.2 million in 2023, then slumped by 30.82% to $283.8 million in 2024, then climbed by 5.79% to $300.2 million in 2025, then declined by 2.79% to $291.8 million in 2026.
• The last three Current Assets figures came in at $291.8 million (Q1 2026), $300.2 million (Q4 2025), and $281.4 million (Q3 2025), per Business Quant data.